First-pass extracted concept

CRISPR-engineered gut commensals as living therapeutics

Candidate: concept label1 source documents6 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

we review recent strategies that harness CRISPR‑engineered gut commensals as precision "living therapeutics" to modulate host immunity and directly target malignant clones

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 6 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1advantage statementsupports2025Source 1DOI PubMed

CRISPR-microbiome editing is presented as offering localized and sustained therapy with reduced systemic toxicity in hematologic oncology.

Claim 2immune function restorationsupports2025Source 1DOI PubMed

Selected controlled preclinical settings reported restoration of CAR-T cell function.

Claim 3preclinical efficacysupports2025Source 1DOI PubMed

Selected preclinical models reported substantial antitumor effects, often greater than 60% tumor reduction in rodent studies.

Claim 4safety and engineering barrierssupports2025Source 1DOI PubMed

Key barriers for clinical deployment include strain stability, biocontainment, and off-target effects.

Claim 5therapeutic strategysupports2025Source 1DOI PubMed

CRISPR-engineered gut commensals are being developed as living therapeutics to modulate host immunity and directly target malignant clones in blood cancers.

Claim 6translation limitationmixed2025Source 1DOI PubMed

Effect sizes vary across models and human translation remains unproven for CRISPR-engineered microbiome approaches in this setting.